Investigation of Prognostic Value of Claudin-5, PSMA, and Ki67 Expression in Canine Splenic Hemangiosarcoma.
Ki67
canine spleen neoplasia
endothelial splenic neoplasia
proliferative index
prostate-specific membrane antigen
Journal
Animals : an open access journal from MDPI
ISSN: 2076-2615
Titre abrégé: Animals (Basel)
Pays: Switzerland
ID NLM: 101635614
Informations de publication
Date de publication:
14 Aug 2021
14 Aug 2021
Historique:
received:
05
07
2021
revised:
09
08
2021
accepted:
10
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Splenic hemangiosarcoma (HSA) is a malignant tumor of endothelial cells that affects middle-aged and elderly dogs and is characterized by the formation of new blood vessels, commonly associated with necrotic and hemorrhagic areas. Despite its importance in veterinary medicine, few studies have identified markers with prognostic value for canine HSA. Thus, this study aimed to associate the clinicopathological findings (prostate-specific membrane antigen [PSMA], Claudin-5, and Ki67 gene and protein expression) with overall survival in HSA-affected patients. Fifty-three formalin-fixed and paraffin-embedded canine splenic HSA samples, previously diagnosed by histopathological examination, were used in this study. Claudin-5, PSMA, and Ki67 protein expression levels were evaluated by immunohistochemistry, and gene expression was evaluated by quantitative polymerase chain reaction. Claudin-5 protein overexpression was observed in patients with metastasis (
Identifiants
pubmed: 34438863
pii: ani11082406
doi: 10.3390/ani11082406
pmc: PMC8388721
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2019/24079-1
Références
Res Vet Sci. 2006 Aug;81(1):76-86
pubmed: 16256156
Aust Vet J. 2004 Apr;82(4):215-7
pubmed: 15149071
Can Vet J. 2018 Sep;59(9):967-972
pubmed: 30197439
ACS Nano. 2015 May 26;9(5):5072-81
pubmed: 25938427
Mol Cell Biochem. 2012 Mar;362(1-2):71-85
pubmed: 22038628
BMC Vet Res. 2020 Nov 18;16(1):447
pubmed: 33208160
J Am Vet Med Assoc. 2005 Nov 1;227(9):1442-8
pubmed: 16279389
BMC Cancer. 2010 Nov 09;10:619
pubmed: 21062482
Philos Trans R Soc Lond B Biol Sci. 2010 May 27;365(1546):1679-96
pubmed: 20403878
Am J Surg Pathol. 2011 Dec;35(12):1848-56
pubmed: 21959309
Histol Histopathol. 2009 Jul;24(7):801-13
pubmed: 19475526
J Am Vet Med Assoc. 2015 Aug 15;247(4):393-403
pubmed: 26225611
APMIS Suppl. 2008;(125):55-62
pubmed: 19385281
J Am Vet Med Assoc. 2021 Mar 15;258(6):630-637
pubmed: 33683962
Vet Sci. 2015 Nov 06;2(4):388-405
pubmed: 29061949
Res Vet Sci. 2016 Jun;106:56-61
pubmed: 27234536
Clin Transl Oncol. 2018 May;20(5):570-575
pubmed: 29058263
J Am Anim Hosp Assoc. 2017 Nov/Dec;53(6):304-312
pubmed: 28892429
Fluids Barriers CNS. 2019 Jan 29;16(1):3
pubmed: 30691500
J Am Vet Med Assoc. 2017 Sep 1;251(5):559-565
pubmed: 28828962
J Comp Pathol. 2013 Jul;149(1):30-9
pubmed: 23276383
Cancer Res. 1999 Jul 1;59(13):3192-8
pubmed: 10397265
PLoS One. 2017 Nov 30;12(11):e0188667
pubmed: 29190660
Vet Surg. 2020 Aug;49(6):1154-1163
pubmed: 32562436
J Vet Intern Med. 2000 Sep-Oct;14(5):479-85
pubmed: 11012108
Vet Med Sci. 2017 Jun 30;3(3):146-155
pubmed: 29067211
Vet Comp Oncol. 2019 Dec;17(4):537-544
pubmed: 31251441
J Vet Intern Med. 2021 Jul;35(4):1929-1934
pubmed: 34227148
J Am Anim Hosp Assoc. 2011 May-Jun;47(3):170-8
pubmed: 21498593
Vet Comp Oncol. 2020 Mar;18(1):43-51
pubmed: 31648405
J Vet Intern Med. 2004 Mar-Apr;18(2):209-13
pubmed: 15058772
Pharmaceuticals (Basel). 2020 Jul 07;13(7):
pubmed: 32645833
Prev Vet Med. 2020 Aug;181:105074
pubmed: 32634752
PLoS One. 2019 Jan 2;14(1):e0210297
pubmed: 30601866